California Public Employees Retirement System maintained its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,200 shares of the biopharmaceutical company’s stock at the end of the second quarter. California Public Employees Retirement System owned about 0.07% of Juno Therapeutics worth $2,128,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Juno Therapeutics by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after acquiring an additional 131,864 shares during the period. BlackRock Inc. lifted its holdings in shares of Juno Therapeutics by 2.6% during the 2nd quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after acquiring an additional 110,503 shares during the period. Jennison Associates LLC purchased a new position in shares of Juno Therapeutics during the 2nd quarter worth about $22,689,000. Geode Capital Management LLC lifted its holdings in shares of Juno Therapeutics by 8.9% during the 1st quarter. Geode Capital Management LLC now owns 595,136 shares of the biopharmaceutical company’s stock worth $13,206,000 after acquiring an additional 48,516 shares during the period. Finally, Pictet Asset Management Ltd. lifted its holdings in shares of Juno Therapeutics by 20.5% during the 2nd quarter. Pictet Asset Management Ltd. now owns 463,435 shares of the biopharmaceutical company’s stock worth $10,766,000 after acquiring an additional 78,690 shares during the period. Institutional investors and hedge funds own 67.18% of the company’s stock.

WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2017/11/02/juno-therapeutics-inc-juno-holdings-maintained-by-california-public-employees-retirement-system.html.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.57) EPS.

Several research analysts have recently weighed in on JUNO shares. Morgan Stanley reiterated an “equal weight” rating and set a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Cowen and Company reiterated a “buy” rating and set a $49.00 price objective on shares of Juno Therapeutics in a report on Friday, October 27th. Vetr upgraded shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price objective on the stock in a report on Monday, August 14th. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 28th. Finally, Raymond James Financial, Inc. upgraded shares of Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price objective on the stock in a report on Tuesday, August 29th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Juno Therapeutics presently has an average rating of “Hold” and a consensus price target of $40.45.

In related news, Director Richard Klausner sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $30.34, for a total value of $364,080.00. Following the completion of the sale, the director now owns 788,985 shares of the company’s stock, valued at approximately $23,937,804.90. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, General Counsel Bernard J. Cassidy sold 28,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $44.92, for a total value of $1,257,760.00. Following the completion of the sale, the general counsel now directly owns 55,970 shares of the company’s stock, valued at approximately $2,514,172.40. The disclosure for this sale can be found here. In the last three months, insiders sold 85,004 shares of company stock valued at $3,551,561. 15.26% of the stock is currently owned by company insiders.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.